Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsCornelis J. M. Melief, M. W. Visseren, W. M. Kast, Pierre van der Bruggen, Thierry Boon-Falleur
Life of this patent
Estimating the term…
Abstract
The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
Claims9
An isolated complex of an HLA-A2 molecule and a peptide, said peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, and SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.